临床荟萃
臨床薈萃
림상회췌
CLINICAL FOCUS
2014年
9期
988-991
,共4页
彭晔%张旭刚%韩轶超%谢娜%杨秀芳%胡洁
彭曄%張旭剛%韓軼超%謝娜%楊秀芳%鬍潔
팽엽%장욱강%한질초%사나%양수방%호길
癌,非小细胞肺%抗肿瘤联合化疗方案%顺铂%老年人
癌,非小細胞肺%抗腫瘤聯閤化療方案%順鉑%老年人
암,비소세포폐%항종류연합화료방안%순박%노년인
carcinoma,non-small-cell lung%antineoplastic combined chemotherapy protocols%cisplatin%aged
目的：观察沙利度胺联合紫杉醇＋顺铂（TP）方案治疗晚期非小细胞肺癌（NSCLC）患者的疗效及安全性。方法随机选择晚期 NSCLC 患者70例，按年龄分为两组，老年组（≥60岁）34例，非老年组（＜60岁）36例，均给予沙利度胺联合 TP 方案治疗，21天为1个周期，至少接受2个周期的治疗。观察两组患者近期疗效、生活质量状况及不良反应。结果老年组和非老年组有效率分别为40．6％（13/32）和42．9％（15/35），疾病控制率分别为87．5％（28/32）和88．6％（31/35），两组中位无进展生存期分别为7．67个月和8．98个月，中位总生存期分别为11．86个月和12．60个月，两组患者治疗后生活质量状况比较差异无统计学意义（P ＞0．05）。不良反应方面，两组均以Ⅰ～Ⅱ级脱发、白细胞减少、肌肉关节痛及恶心呕吐为主，均在可耐受范围，两组不良反应发生率差异无统计学意义（P ＞0．05）。结论老年晚期 NSCLC 患者给予沙利度胺联合 TP 方案治疗得到与非老年晚期 NSCLC 患者一样的治疗效果。
目的：觀察沙利度胺聯閤紫杉醇＋順鉑（TP）方案治療晚期非小細胞肺癌（NSCLC）患者的療效及安全性。方法隨機選擇晚期 NSCLC 患者70例，按年齡分為兩組，老年組（≥60歲）34例，非老年組（＜60歲）36例，均給予沙利度胺聯閤 TP 方案治療，21天為1箇週期，至少接受2箇週期的治療。觀察兩組患者近期療效、生活質量狀況及不良反應。結果老年組和非老年組有效率分彆為40．6％（13/32）和42．9％（15/35），疾病控製率分彆為87．5％（28/32）和88．6％（31/35），兩組中位無進展生存期分彆為7．67箇月和8．98箇月，中位總生存期分彆為11．86箇月和12．60箇月，兩組患者治療後生活質量狀況比較差異無統計學意義（P ＞0．05）。不良反應方麵，兩組均以Ⅰ～Ⅱ級脫髮、白細胞減少、肌肉關節痛及噁心嘔吐為主，均在可耐受範圍，兩組不良反應髮生率差異無統計學意義（P ＞0．05）。結論老年晚期 NSCLC 患者給予沙利度胺聯閤 TP 方案治療得到與非老年晚期 NSCLC 患者一樣的治療效果。
목적：관찰사리도알연합자삼순＋순박（TP）방안치료만기비소세포폐암（NSCLC）환자적료효급안전성。방법수궤선택만기 NSCLC 환자70례，안년령분위량조，노년조（≥60세）34례，비노년조（＜60세）36례，균급여사리도알연합 TP 방안치료，21천위1개주기，지소접수2개주기적치료。관찰량조환자근기료효、생활질량상황급불량반응。결과노년조화비노년조유효솔분별위40．6％（13/32）화42．9％（15/35），질병공제솔분별위87．5％（28/32）화88．6％（31/35），량조중위무진전생존기분별위7．67개월화8．98개월，중위총생존기분별위11．86개월화12．60개월，량조환자치료후생활질량상황비교차이무통계학의의（P ＞0．05）。불량반응방면，량조균이Ⅰ～Ⅱ급탈발、백세포감소、기육관절통급악심구토위주，균재가내수범위，량조불량반응발생솔차이무통계학의의（P ＞0．05）。결론노년만기 NSCLC 환자급여사리도알연합 TP 방안치료득도여비노년만기 NSCLC 환자일양적치료효과。
Objective To study the curative effect and safety of thalidomide combined with paclitaxel plus cis-platinum(TP)chemotherapy in patients with advanced non-small cell lung cancer(NSCLC).Methods Seventy patients in late NSCLC period were divided randomly into two groups according to the age.The elderly group (≥60 years)34 patients and non-elderly group (< 60 years ) 36 patients were treated with thalidomide combined with TP chemotherapy.All patients received treatments for at least two periods,21 days for one period.The efficacy,the quality of life and adverse effects of two groups were observed.Results The effective rate for advanced NSCLC in the elderly group and the non-elderly group was 40.6%(13/32)and 42.9%(15/35),respectively.Control rate of the disease was 87.5%(28/32)and 88.6%(31/35),the median progression-free survival was 7.67 months and 8.98 months,and the median overall survival was 11.86 months and 12.60 months,respectively.The patients of two groups improved quality of life compared with the previous situation,but the quality of life showed no significant differences after treatment between two groups(P > 0.05).In the adverse effects,the Ⅰ-Ⅱ toxic reactions of chemotherapy were tolerable, including alopecia,leukopenia,muscle and joint pain,nausea and vomiting,but two groups were similar(P > 0.05). Conclusion If elderly patients with late NSCLC period are treated with thalidomide plus TP chemotherapy,they get as safe and effective treatment as non-elderly patients with late NSCLC period.
